A TRIAL FOR HEART FAILURE PATIENTS WITH PRESERVED SYSTOLIC FUNCTION

TOPCAT is a multi-center, international, randomized, double blind placebo-controlled trial of the aldosterone antagonist, spironolactone, in 3,445 adult subjects with heart failure and left ventricular ejection fraction of at least 45%, recruited internationally from over 200 clinical centers in the US, Canada, Russia, Republic of Georgia, Argentina, and Brazil.

The trial is sponsored by the National Heart, Lung, and Blood Institute of the National Institutes of Health. New England Research Institutes, Inc. (NERI) and The Brigham & Women’s Hospital (BWH) serve as the Clinical Trial Coordinating Center (CTCC) for this study.

Enrollment started in August 2006 and recently ended on January 31, 2012.